Diabetic Cardiomyopathies
15
4
5
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.7%
1 terminated out of 15 trials
80.0%
-6.5% vs benchmark
7%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (15)
Mitochondrial Substrate Utilization in the Diabetic Human Heart
Tailored Exercise Training Study Among Adults With HFpEF
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
The DAPA-MEMRI Trial
Diabetic Cardiomyopathy and Heart Failure
Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy
Prevalence and Determinants of Subclinical Cardiovascular Dysfunction in Adults With Type 2 Diabetes Mellitus
CMR in T2DM: The NSR Cohort
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
Efficacy of Trimetazidine in Diabetic Patients
Diabetic Cardiomyopathy
Effect of High-intensity Interval Training on Cardiac Function and Regulation of Glycemic Control in Diabetic Cardiomyopathy
In and ex Vivo Mitochondrial Function of the Heart
Single-center Clinical Study of Early Diagnosis of Diabetic Cardiomyopathy With FLIM
Preclinical Cardiomyopathy and Autonomic Function in Type 1 Diabetes